Intellia Therapeutics: Promising Phase 2 Results and Attractive Valuation Spur Buy Recommendation
JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...
Intellia Therapeutics presents results from Phase 2 study of NTLA-2002
Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary ...
A Closer Look at Intellia Therapeutics's Options Market Dynamics
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $17.5 to $20.0 for Intellia Therapeutics over the recent three months.
FierceBiotech2h
Poseida's HAE gene therapy edits primate livers and reduces kallikrein protein levels in mice, company says
Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...
SchaeffersResearch.com3h
2 Biotech Stocks Making Big Moves
Biotech stocks Viking Therapeutics (VKTX) and Intellia Therapeutics (NTLA are both making outsized moves today ...
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.
Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release
Based on these findings, Intellia chose the 50 mg dose for their Phase 3 research, HAELO, which is now under enrollment ...
Intellia data spark debate about CRISPR drug’s potential
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy
Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...
FierceBiotech7h
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
Medpage Today on MSN16h
Gene-Editing Therapy Reduced Attacks in Hereditary Angioedema
A single dose of the CRISPR-based gene-editing therapy NTLA-2002 reduced angioedema attacks and led to sustained reduction in ...
Regeneron's Eye Disease Drug Eylea and Immunology Drug Dupixent Support a Narrow Moat
Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...